Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.60 Consensus PT from Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $36.60.

A number of brokerages recently weighed in on VRDN. B. Riley reduced their target price on shares of Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, March 21st. Wedbush increased their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Viridian Therapeutics in a research report on Thursday, February 29th.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds have recently modified their holdings of VRDN. SG Americas Securities LLC grew its holdings in shares of Viridian Therapeutics by 150.5% in the 3rd quarter. SG Americas Securities LLC now owns 102,667 shares of the company’s stock valued at $1,575,000 after acquiring an additional 61,676 shares in the last quarter. Raymond James & Associates grew its holdings in Viridian Therapeutics by 71.1% during the third quarter. Raymond James & Associates now owns 15,164 shares of the company’s stock worth $233,000 after purchasing an additional 6,303 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Viridian Therapeutics by 17.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 29,227 shares of the company’s stock worth $448,000 after purchasing an additional 4,412 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in Viridian Therapeutics by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 27,112 shares of the company’s stock worth $416,000 after purchasing an additional 12,807 shares during the period. Finally, Knights of Columbus Asset Advisors LLC grew its holdings in Viridian Therapeutics by 2.9% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company’s stock worth $453,000 after purchasing an additional 823 shares during the period.

Viridian Therapeutics Trading Up 5.6 %

NASDAQ:VRDN opened at $15.40 on Monday. The business’s 50-day simple moving average is $16.73 and its 200-day simple moving average is $17.61. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $28.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.26 and a quick ratio of 18.26. The stock has a market capitalization of $982.83 million, a PE ratio of -2.89 and a beta of 1.14.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.37). Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. During the same period in the previous year, the firm posted ($1.13) EPS. The business’s quarterly revenue was down 31.4% compared to the same quarter last year. Sell-side analysts expect that Viridian Therapeutics will post -4.39 earnings per share for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.